A novel EGFR Inhibitor, HNPMI regulates apoptosis and oncogenesis by modulating BCL-2/BAX and p53 in colon cancer.

Jeyalakshmi KandhaveluKumar SubramanianVivash NaidooGiulia SebastianelliPhuong DoanSaravanan Konda ManiHande YapislarEbru HaciosmanogluLeman ArslanSamed OzerRamesh ThiyagarajanNuno R CandeiasClement PennyMeenakshisundaram KandhaveluAkshaya Murugesan

Published in: British journal of pharmacology (2023)

HNPMI is the promising EGFR inhibitor for clinical translation. HNPMI regulates apoptosis and oncogenesis by modulating BCL-2/BAX and p53 in CRC, thus suggesting it as a therapeutic drug target for treating CRC.

Keyphrases

small cell lung cancer
endoplasmic reticulum stress
induced apoptosis
epidermal growth factor receptor
oxidative stress
cell cycle arrest
tyrosine kinase
cell death
signaling pathway
pi k akt
emergency department
cell proliferation